Core Viewpoint - Dongrui Pharmaceutical (02348.HK) reported a revenue of RMB 630 million for the six months ending June 30, 2025, representing a year-on-year increase of 9.2% [1] Financial Performance - Gross profit amounted to RMB 314 million, showing a year-on-year decrease of 7.1% [1] - Profit attributable to the parent company for the period, excluding non-recurring gains from the sale of associates and equipment validation subsidies, was RMB 105 million, down 17.1% year-on-year [1] - Total profit attributable to the parent company was RMB 105 million, reflecting a significant year-on-year decrease of 78.8% [1] - Basic earnings per share were RMB 0.06961, with an interim dividend proposed at HKD 0.015 per share [1] Operational Challenges - The decline in profit was primarily due to the lack of scaled commercial production at the Suzhou Dongrui and Lanzhou Dongrui facilities, price reductions in certain provinces for the "An" series products influenced by national policies, and increased R&D expenses [1]